Canton Strategic (CNTN) vs PepGen (PEPG)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Canton Strategic (CNTN) has outperformed PepGen (PEPG) over the past year, losing 25.2% versus a loss of 51.1%. Canton Strategic is the larger company by market cap ($165.7 million vs $164.6 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CNTN | PEPG |
|---|---|---|
| Share price | $2.08 | $2.38 |
| Market cap | $165.74M | $164.62M |
| 1-day change | -7.96% | -0.83% |
| YTD return | -25.41% | -63.44% |
| 1-year return | -25.17% | -51.13% |
| EPS (TTM) | $-0.10 | $-1.01 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $6.89 | $7.80 |
| 52-week low | $1.75 | $1.31 |
| Distance from 52-week high | -69.81% | -69.49% |
| Analyst consensus | — | none |
| Avg. price target upside | — | +328.15% |
| Average volume | 751.76K | 971.65K |
| Shares outstanding | 79.68M | 69.17M |
| Employees | 12 | 57 |
| Sector | Healthcare | Health Care |
| Industry | Biotechnology | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CNTN has outperformed PEPG by 26.0 percentage points over the past year.
- The two companies sit in different sectors: Canton Strategic in Healthcare and PepGen in Health Care.
About Canton Strategic
CNTN stock →Canton Strategic Holdings, Inc. engages in the institutional blockchain adoption and digitization of financial markets in the United States.
Healthcare · Biotechnology · 12 employees
About PepGen
PEPG stock →PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. The company engages in the development of PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and FREEDOM2-DM1, which is in Phase 2 for the treatment of myotonic dystrophy type 1.
Health Care · Biotechnology: Pharmaceutical Preparations · 57 employees
CNTN vs PEPG FAQ
Which is bigger, Canton Strategic or PepGen?
Canton Strategic (CNTN) is larger, with a market capitalization of $165.74M compared with $164.62M for PepGen (PEPG).
Which stock has performed better over the past year, CNTN or PEPG?
CNTN returned -25.17% over the past 12 months, compared with -51.13% for PEPG (price return, excluding dividends). Past performance does not predict future results.
Are Canton Strategic and PepGen in the same industry?
No. Canton Strategic is in the Healthcare sector, while PepGen is in Health Care.